FindTrial
Sign In

Diagnostic value of plasm soluble receptor for advanced glycation end products (sRAGE) in coronary and cerebral atherosclerosis and its association with activations of inflammation and platelet

Diagnostic value of soluble receptor for advanced glycation end products (sRAGE) in coronary and cerebral atherosclerosis and its association with activations of inflammation and platelet

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026745
Enrollment
Unknown
Registered
2019-10-20
Start date
2019-11-03
Completion date
Unknown
Last updated
2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary and cerebral atherosclerosis

Interventions

Gold Standard:coronary angiography and craniocerebral CT angiography (or total cerebral angiography)
Index test:plasm&#32
soluble&#32
receptor&#32
for&#32
advanced&#32
glycation&#32
end&#32
products&#32
(sRAGE)

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. consecutive patients who synchronously undertook coronary angiography and craniocerebral CT angiography (or total cerebral angiography) in Beijing Tiantan Hospital, Capital Medical University in this study; 2. over the age of 18 years; 3. all patients gave their written informed consent.

Exclusion criteria

Exclusion criteria: (1) severe liver and/or renal insufficiency; (2) patients with persistent or permanent atrial fibrillation; (3) severe valvular heart disease with hemodynamic stability; (4) significant hematologic disorders; (5) patients taking warfarin, dabigatone and other anticoagulants for a long timeany; (6) malignant tumors; (7) pregnant women, newborns, children and other vulnerable groups

Design outcomes

Primary

MeasureTime frame
plasm soluble receptor for advanced glycation end products (sRAGE);Inflammation factor (IFN-gama, IL-17, IL-18, IL-23 and sCRP);platelet activating factors (sCD36, CD40L, P-sclectin);—

Countries

China

Contacts

Public ContactCai-Xia Guo

Beijing Tiantan Hospital, Capital Medical University

cxgbb@163.com+86 13691175496

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026